Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies

Xencor Inc

2025-Q3 EPS reported -$1.15 revenue$97,339,000

Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
Cash $633.9M at Sept 30, 2025; expects year-end cash $570-590M and runway into 2028.
XmAb819 (ccRCC) and XmAb541 (gynecologic/germ cell) show early PRs; Phase 3 dose selection in 2026; pivotal studies targeted for 2027.
First patient dosed in plamotamab Phase 1b RA study; XmAb942 Phase 2b XENITH-UC enrolling; XmAb657 and XmAb412 studies on track.
Partners advancing: Amgen Phase 3 XALience for xaluritamig; Astellas data on ASP2138; Zenas positive Phase 2 in MS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.